Literature DB >> 30273572

Intensity of Glycemic Control Affects Long-Term Survival After Coronary Artery Bypass Graft Surgery.

Michael P Robich1, Alexander Iribarne2, Bruce J Leavitt3, David J Malenka2, Reed D Quinn4, Elaine M Olmstead2, Cathy S Ross2, Douglas B Sawyer4, John D Klemperer5, Robert A Clough3, Robert S Kramer4, Yvon R Baribeau6, Gerald L Sardella7, Anthony W DiScipio2.   

Abstract

BACKGROUND: A patient's hemoglobin (Hb) A1c level, regardless of diabetic status, is a measure of glycemic control. Studies have found it is an independent predictor of short-term death in patients undergoing coronary artery bypass grafting (CABG). In this study, we used preoperative HbA1c to assess whether levels are associated with short-term and long-term survival after CABG.
METHODS: From a regional registry of consecutive cases, we identified 6,415 patients undergoing on-pump isolated CABG from 2008 to 2015 with documented preoperative HbA1c level. We defined four HbA1c groups: less than 5.7% (n = 1,713), 5.7% to 6.4% (n = 2,505), 6.5% to 8.0% (n = 1,377), and more than 8% (n = 820). Relationship to in-hospital outcomes and long-term survival was assessed. Outcome rates and hazard ratios were adjusted for patient and disease risk factors using multivariable logistic regression and Cox models.
RESULTS: The study included 3,740 patients (58%) not diagnosed as having diabetes and 2,674 with diabetes. Prediabetes (HbA1c 5.7% to 6.4%) was documented in 52% (n = 1,933) of nondiabetic patients. Higher HbA1c values were associated with younger age, female sex, greater body mass index, more comorbid diseases, lower ejection fraction, more 3-vessel coronary disease, and recent myocardial infarction (p < 0.05 trend for all). After adjustment for patient risk, greater HbA1c values were not associated with higher rates of in-hospital death or morbidity. Long-term survival was significantly worse as HbA1c increased. Risk of death increased by 13% for every unit increase in HbA1c (adjusted hazard ratio, 1.13; 95% confidence interval, 1.07 to 1.19; p < 0.001).
CONCLUSIONS: Preadmission glycemic control, as assessed by HbA1c, is predictive of long-term survival, with higher levels associated with poorer prognosis. Whether this risk can be modified by better glycemic control postoperatively remains to be determined.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30273572     DOI: 10.1016/j.athoracsur.2018.07.078

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Perioperative care in cardiac surgery.

Authors:  S Pokhrel; A Gregory; A Mellor
Journal:  BJA Educ       Date:  2021-07-13

2.  Hypotension after intensive care unit drop-off in adult cardiac surgery patients.

Authors:  Sabina Cengic; Muhammad Zuberi; Vikas Bansal; Robert Ratzlaff; Eduardo Rodrigues; Emir Festic
Journal:  World J Crit Care Med       Date:  2020-06-05

3.  Glycemic Control in Coronary Artery Bypass Graft Surgery: A Different Perspective.

Authors:  Vali Imantalab; Abbas Sedighinejad; Ali Mohammadzadeh Jouryabi; Gelareh Biazar; Gholamreza Kanani; Mohammad Haghighi; Haniyeh Sadat Fayazi; Golnoosh Ghasvareh
Journal:  Anesth Pain Med       Date:  2022-01-03

4.  A1C as a Prognosticator of Perioperative Complications of Diabetes: A Narrative Review.

Authors:  Raghuraman M Sethuraman; Satyen Parida; Adinarayanan Sethuramachandran; Priyanka Selvam
Journal:  Turk J Anaesthesiol Reanim       Date:  2022-04

5.  Glycated haemoglobin and the risk of postoperative complications in people without diabetes: a prospective population-based study in UK Biobank.

Authors:  S Lam; B Kumar; Y K Loke; S E Orme; K Dhatariya
Journal:  Anaesthesia       Date:  2022-03-03       Impact factor: 12.893

6.  Perioperative Cardiometabolic Targets and Coronary Artery Bypass Surgery Mortality in Patients With Diabetes.

Authors:  John P Skendelas; Donna K Phan; Patricia Friedmann; Carlos J Rodriguez; Daniel Stein; Armin Arbab-Zadeh; Stephen J Forest; Leandro Slipczuk
Journal:  J Am Heart Assoc       Date:  2022-04-27       Impact factor: 6.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.